Ikena Oncology to Participate in Spring 2022 Investor Conferences

Rhea-AI Summary

Ikena Oncology (Nasdaq: IKNA) announced its participation in two upcoming conferences: the H.C. Wainwright Global Investment Conference from May 23-26, 2022, and the Jefferies Global Healthcare Conference from June 8-10, 2022. CEO Mark Manfredi will present a corporate update at the Wainwright conference on May 25, 2022, at 11:30 a.m. ET, and participate in a fireside chat at the Jefferies Conference on June 9, 2022, at 10:00 a.m. ET. Webcasts will be available on Ikena's website.

BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will be presenting at the H.C. Wainwright Global Investment Conference, taking place May 23-26, 2022, and the Jefferies Global Healthcare Conference, taking place June 8-10, 2022.

Ikena CEO Mark Manfredi, Ph.D., will present a corporate update at the H.C. Wainwright Global Investment Conference and management will attend virtually. They will also participate in a fireside chat at the Jefferies Global Healthcare Conference and will attend the conference live in New York City.

Details can be found below:

H.C Wainwright Global Investment Conference

Corporate Presentation

Date: May 25, 2022, 11:30 a.m. ET

Webcast Link

Jefferies Global Healthcare Conference

Fireside Chat

Date: June 9, 2022, 10:00 a.m. ET

Webcast Link

The presentation webcasts will be available on the Company’s Events & Presentations page on their website at www.ikenaoncology.com.

About Ikena Oncology
Ikena Oncology^TM is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer. The Company’s lead targeted oncology program, IK-930, is a TEAD inhibitor addressing the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company’s ongoing discovery research spans other targets in the Hippo pathway as well as the RAS signaling pathway. Additional programs targeting the tumor microenvironment and immune signaling are in the clinic, including IK-175, an aryl hydrocarbon receptor antagonist, which is being developed in collaboration with Bristol Myers Squibb. Ikena’s pipeline is built on addressing genetically defined or biomarker-driven cancers and developing therapies that can serve specific patient populations in need of new therapeutic options. To learn more, visit www.ikenaoncology.com or follow us on Twitter and LinkedIn.

Investor Contact:
Rebecca Cohen
Ikena Oncology
rcohen@ikenaoncology.com

Media Contact:
Gwen Schanker
LifeSci Communications
gschanker@lifescicomms.com

FAQ

What conferences will Ikena Oncology participate in during 2022?

Ikena Oncology will participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022, and the Jefferies Global Healthcare Conference from June 8-10, 2022.

When will Ikena Oncology present at the H.C. Wainwright Global Investment Conference?

Ikena Oncology will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 11:30 a.m. ET.

When is the Ikena Oncology fireside chat at the Jefferies Global Healthcare Conference?

The fireside chat at the Jefferies Global Healthcare Conference will take place on June 9, 2022, at 10:00 a.m. ET.

Where can I watch Ikena Oncology's conference presentations?

Ikena Oncology's conference presentations will be available via webcasts on their Events & Presentations page on their website.

What is Ikena Oncology's primary area of focus?

Ikena Oncology focuses on developing therapies targeting key signaling pathways involved in cancer formation and progression.